drug discovery

Insilico Medicine names preclinical candidate targeting KAT6A for treatment of ER+/HER2- breast cancer with end-to-end AI engine

Insilico Medicine names preclinical candidate targeting KAT6A for treatment of ER+/HER2- breast cancer with end-to-end AI engine

New York, 27 Dec. 10, 2022 (GLOBE NEWSWIRE) — Insilico Medicine (“Insilico”), an end-to-end artificial intelligence (AI)-focused drug discovery company, today announced that the drug discovery team at company has named a preclinical candidate targeting KAT6A for the treatment of ER+/HER2- breast cancer using its end-to-end Pharma.AI platform. The Company has now named eight preclinical …

Insilico Medicine names preclinical candidate targeting KAT6A for treatment of ER+/HER2- breast cancer with end-to-end AI engine Read More »

Insilico Medicine names a potential first-class preclinical candidate with a novel AI-designed structure for a novel target discovered by AI in immuno-oncology

Insilico Medicine names a potential first-class preclinical candidate with a novel AI-designed structure for a novel target discovered by AI in immuno-oncology

New York, 20 Dec. 10, 2022 (GLOBE NEWSWIRE) — Insilico Medicine (“Insilico”), an end-to-end clinical-stage artificial intelligence (AI)-focused drug discovery company, today announced that it has named ISM4312A in as a preclinical candidate targeting DGKA with an AI-identified target and an AI-designed structure for immuno-oncology therapeutics. This is another fully discovered and AI-engineered program that …

Insilico Medicine names a potential first-class preclinical candidate with a novel AI-designed structure for a novel target discovered by AI in immuno-oncology Read More »

Increasing production of custom immune cells for drug development and testing

Increasing production of custom immune cells for drug development and testing

To prevent animal testing and create even more accurate ways to test therapeutics, the pharmaceutical industry is increasingly turning to human immune cells. However, the availability of cells like these has been limited to date. Now, Fraunhofer researchers have succeeded in taking the production of personalized immune cells from the laboratory to the industrial level. …

Increasing production of custom immune cells for drug development and testing Read More »